ATNM-400, a First-in-Class Actinium-225 HER3 Antibody Radioconjugate Triggers Durable Antitumor Responses in Ovarian Cancer Models

Actinium Pharmaceuticals Inc. published this content on October 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 19, 2026 at 15:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]